We sought to determine whether seliciclib (CYC202, R-roscovitine) could increase the antitumor effects of doxortibicin, with no increase in toxicity, in ail MCF7 breast cancer xenograft model. The efficacy of seliciclib combined with doxorubicin was compared with single agent doxorubicin or seliciclib administered to MCF7 cells and to nude mice hearing established MCF7 xenografts. Post-treatment cells and tumors were examined by cell cycle analysis, immunohistochemistry and real-time PCR. Seliciclib significantly enhanced the antitumor effect of doxorubicin without additional murine toxicity. MIB1 (ki67) immunohistochemistry demonstrated reduced proliferation with treatment. The levels of p21 and p27 increased after treatment with doxorubicin or seliciclib alone or in combination, compared to untreated controls. However, no changes in p53 protein (DO1, CM1), survivin or p53 phosphorylation (SER15) were observed in treated tumors compared with controls. In conclusion, the CDK inhibitor seliciclib (R-roscovitine) enhances the antitumor effect of doxortibicin in MCF7 tumors without increased toxicity with a mechanism that involves cell cycle arrest rather than apoptosis. (c) 2008 Wiley-Liss, Inc.
|Number of pages||8|
|Journal||International Journal of Cancer|
|Publication status||Published - 15 Jan 2009|
- CDK inhibitor
- combination therapy
- DEPENDENT KINASE INHIBITOR
- ANTICANCER DRUGS